HealthQuill Regeneron
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, according to a company statement.
Drugs Health Pharma

EMA approves Sanofi’s treatment for obstructive pulmonary disease

The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.

Read More
BioNTech, a Germany-based biotechnology company, is expected to spend between 2.4 million euros and 2.6 million euros on research this year compared with 1.5 million euros last year.
Drugs Medical Pharma

BioNTech in one million euro push for research on drugs

BioNTech, a Germany-based biotechnology company, is expected to spend between 2.4 million euros and 2.6 million euros on research this year compared with.

Read More
X